• Citations Per Year
Learn More
AIM To develop new approach for tumor immunotherapy with VEGFR2-based DNA vaccine. METHODS VEGFR2 derived from different species were prepared by RT-PCR and subjected to recombinant constructs. The chimeric gene of VEGFR2 was prepared by integrating different epitopes in different species. By transfecting into cells, the immunological effect was evaluated(More)
The complexity of rheumatoid arthritis (RA) pathogenesis makes combined blockade of multiple targets an attractive therapeutic strategy. The combination therapy with anti-TNF plus anti-T-cell has been mostly reported to provide greater efficacy than anti-TNF alone. TNFR (p75)-Fc fusion protein, which has been proven effective in clinics, is chosen as the(More)
The successful use of tumor-draining lymph nodes (TDLN) as a source of effector cells for cancer immunotherapy depends largely on the immunogenicity of the tumor drained by the lymph nodes as well as the methods for secondary in vitro T cell activation and expansion. We transferred the bacterial superantigen staphylococcal enterotoxin A (SEA) gene into B16(More)
Radiotherapy is a key modality for head and neck cancer (HNC) treatment. Mitogen activated protein kinase phosphatase-1 (MKP-1) protein levels are elevated in various tumors and are negatively correlated with efficacy of chemo- or radio-therapy. However, the mechanisms underlying the moderate radiosensitivity of HNC and the increased MKP-1 protein levels(More)
A DNA-based replicon vaccine derived from Semliki Forest virus, PSVK-shFcG-GM/B7.1 (Fig. 1a) was designed for tumor immunotherapy as previously constructed. The expression of the fusion tumor antigen (survivin and hCGβ-CTP37) and adjuvant molecular protein (Granulocyte-Macrophage Colony-Stimulating Factor/ GM-CSF/B7.1) genes was confirmed by(More)
OBJECTIVE To obtain β-chain human chorionic gonadotropin (β-hCG) fusion protein (β-hCG/GST) and identify its antigenicity. METHODS The full-length gene of β-hCG was amplified by PCR. The PCR product was cloned into pET-42a prokaryotic expression vector to construct the recombinant plasmid pET-42a-β-hCG, and then it was transformed into BL21 (DE3) for(More)
OBJECTIVE To obtain 1-4 IgG-like domains of mouse vascular endothelial growth factor receptor 2 (VEGFR2) fusion protein (mVEGFR2D1-4/GST) and identify its antiginicity and biological activity. METHODS The gene of mVEGFR2D1-4 was amplified by RT-PCR from 14-days embryos of Balb/c mice. The PCR product was cloned into pET-42a prokaryotic expression vector(More)
OBJECTIVE To amplify human renal cell carcinoma (RCC)-associated antigen G250 gene and construct a recombinant plasmid pET-42a-hG250, express and purify human G250 protein and identify its antigenicity. METHODS The gene of human G250 was amplified from pGEM-T-G250 by PCR. After sequencing, the PCR product (112-1242 bp) was cloned into pET-42a prokaryotic(More)
OBJECTIVE To construct a eukaryotic expression plasmid harboring HBV fusion antigen gene, and to express it in 293T cells. METHODS The HBV fusion gene fragment was amplified by PCR from the plasmid pVAX1-HBV containing HBV fusion gene. After purified, the product was cloned into pMD18-T vector. The recombinant plasmid was confirmed by endonuclease(More)
OBJECTIVE To construct a recombinant replication-defective adenovirus vector carrying p53AIP1 (p53-regulated apoptosis-inducing protein 1) gene and observe its expression in human HeLa cells. METHODS Specific primers were designed according to p53AIP1 gene sequence and inserted specific enzyme cutting sites. P53AIP1 gene was amplified by PCR and cloned(More)